MPO and brain ischemia: Similarly, SF has been suggested as a potential candidate for adjuvant therapy against cerebral ischemia–reperfusion injury, and experimental results showed SF to improve outcomes and slow cerebral ischemic/reperfusion injury via inhibition of NLRP3 inflammasomes and reduced MPO levels, reflecting neutrophil infiltration in the ischemic cerebral cortex [144,145].